A selective BCL-XL PROTAC degrader achieves safe and potent antitumor activity.

Nat Med. 2019 Dec;25(12):1938-1947.

Khan S¹, Zhang X², Lv D¹, Zhang Q³, He Y¹, Zhang P², Liu X¹, Thummuri D¹, Yuan Y¹, Wiegand JS¹, Pei J¹, Zhang W⁴, Sharma A⁵, McCurdy CR², Kuruvilla VM³, Baran N³, Ferrando AA⁶, Kim YM⁷, Rogojina A⁸, Houghton PJ⁸, Huang G⁹, Hromas R⁹, Konopleva M³, Zheng G¹⁰, Zhou D¹¹.

1. Department of Pharmacodynamics, University of Florida, Gainesville, FL, USA.
2. Department of Medicinal Chemistry, College of Pharmacy, University of Florida, Gainesville, FL, USA.
3. Department of Leukemia, University of Texas M.D. Anderson Cancer Center, Houston, TX, USA.
4. Department of Pathology, Immunology and Laboratory Medicine, College of Medicine, University of Florida, Gainesville, FL, USA.
5. Department of Pharmaceutics, College of Pharmacy, University of Florida, Gainesville, FL, USA.
6. Department of Pediatrics, Pathology, Cell Biology and Systems of Biology and Institute for Cancer Genetics, Columbia University, New York, NY, USA.
7. Department of Pediatrics, Children's Hospital Los Angeles, Los Angeles, CA, USA.
8. Greehey Children's Cancer Research Institute, University of Texas Health Science Center at San Antonio, San Antonio, TX, USA.
9. Department of Medicine, the Long School of Medicine, University of Texas Health Science Center at San Antonio, San Antonio, TX, USA.
10. Department of Medicinal Chemistry, College of Pharmacy, University of Florida, Gainesville, FL, USA. zhengg@cop.ufl.edu.
11. Department of Pharmacodynamics, University of Florida, Gainesville, FL, USA. zhoudaohong@cop.ufl.edu.

Presented by Sajid Khan